소형 연안어선의 저항성능에 관한 실험적 연구

김도정 ( Do Jung Kim ),박제웅 ( Je Woong Park ),김주남 ( Ju Nam Kim ),정우철 ( Uh Cheul Jeong ) 한국어업기술학회 2004 수산해양기술연구 Vol.40 No.4

복수가 동반된 간경변증을 가진 말기 신부전 환자에서 복막투석의 안정성

김정인 ( Jung In Kim ),이정은 ( Jung Eun Lee ),백현정 ( Hyun Jeong Baek ),최성철 ( Sung Chul Choi ),도정호 ( Jung Ho Do ),허우성 ( Woo Seong Huh ),김윤구 ( Yoon Goo Kim ),김대중 ( Dae Joong Kim ),오하영 ( Ha Young Oh ) 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.3

Purpose : When liver cirrhosis patients accompanying ascites need renal replacement therapy because of chronic renal failure (CRF), peritoneal dialysis (PD) can allow direct removal of ascites and prevent anticoagulants use. However, since PD might aggravate hypoalbuminemia and increase chances of peritonitis, clinicians tend to hesitate to apply it to those patients. The aim of the present study is to assess the outcome and stability of PD for the treatment of CRF patient with cirrhosis accompanying ascites. Methods : A retrospective study based on the clinical records was performed in cirrhotic patients with ascites in whom PD was performed for the treatment of CRF and who were followed up at Samsung Medical Center unit, between January 1995 and July 2005. Results : In our study, 15 patients were enrolled. Child-pugh class was worse in non-survival group than survival group (p<0.01). One-year patient survival was 40% in Class C and 75% in Class B, and patient survival differed between Class C and Class B (p=0.0014). Causes of death were terminal liver failure (n=6) and sepsis due to pneumonia (n=1). Total 27 episodes of peritonitis occurred, and the peritonitis rates were 0.91 episodes/patients-year. Conclusion : Although the peritonitis rates turned out somewhat high, the use of PD for the treatment of CRF in patients with liver cirrhosis accompanying ascites seems to be safe and effective. Main cause of death in our study seems to be related to liver disease.

해양환경정화용 선박의 중앙개구부 특성에 관한 실험적 연구

김도정(DO-JUNG KIM),박제웅(JE-WOONG PARK),김주남(JU-NAM KIM),정우철(UH-CHUL JEONG) 한국해양공학회 2006 韓國海洋工學會誌 Vol.20 No.2

Moonpool characteristics of a cleaning ship related with the performance of a ship are experimentally investigated. Resistance performances of the ship and flow patterns in the moonpool are observed, in order to determine the effect of different shaped moonpool. The ways to reduce ship pitching motion caused by flows in the moonpool are examined. Experimental results, using a scale model of cleaning ship with moonpool, show that the step arranged in tier under water leads to significant improvements in performance, such as resistance and ship pitching motion. Depending upon the shape of step in the moonpool, the results indicate that the increment of resistance performance may be up to 35%, especially in the case of no step or high step.

제품구성모델 기반의 쌍동형 레저보트 건조공수 추정 연구

김도정(Do Jung Kim),오우준(Woo Jun Oh),최지훈(Ji Hun Choi),오대균(Dae Kyun Oh),이동건(Dong Kun Lee) 대한기계학회 2014 대한기계학회 춘추학술대회 Vol.2014 No.4-3

수중 가시화 구명줄 시스템의 설계 및 제작

김우현(Woo-Hyun Kim),왕국명(Guoming Wang),길경석(Gyung-Suk Kil),김도정(Do-Jung Kim),서봉원(Bong-Won Seo),김수영(Su-Young Kim),김영문(Young-Moon Kim) 한국마린엔지니어링학회 2018 한국마린엔지니어링학회지 Vol.42 No.9

지속성 외래 복막투석 환자에서 고용량(10,000 IU) Epoetin alfa의 효과에 대한 교차 연구

도정호 ( Jung Ho Do ),김대중 ( Dae Joong Kim ),최소연 ( So Yeon Choi ),도연실 ( Yeon Sil Do ),장은희 ( Eun Hee Jang ),백현정 ( Hyun Jeong Baek ),김정인 ( Jung In Kim ),여호명 ( Ho Myoung Yeo ),최성철 ( Sung Chul Choi ),이정은 ( Ju 대한내과학회 2006 대한내과학회지 Vol.71 No.5

목적: 유전자 재조합 인 에리스로포이에틴(rHuEPO)은 신성빈혈 치료에 필수 불가결한 약제이다. rHuEPO는 당화 폴리펩타이드로 피하 또는 정맥 내로 투여하여야 하며 이에 따른 불편함을 개선하기 위하여 최근에는 darbepoetin 또는 고용량의 epoetin beta로 투여 간격을 늘리는 방법이 소개되고 있다. 본 연구는 대상 환자간의 변이를 최소화 할 수 있는 교차 연구를 통하여 고용량 epoetin alfa 피하 투여의 빈혈 교정 효과를 볼 수 있는지 확인하고자 하였다. 방법: RHuEPO를 투여 중인 지속성 외래 복막투석환자 24명을 고용량-기존용량(n=12) 또는 기존용량-고용량(n=12) 피하투여군으로 무작위 분류하여 처음 6개월간은 총 10회 방문(스크리닝 1회, 이후 9회) 치료하였고(Period I), 이후 6개월간은 두 군을 교차시켜 4회 방문 치료(Period II)하였다. 고용량은 10,000 IU, 기존용량은 4,000 IU로 투여하였고, 헤마토크릿이 30~39% 범위를 유지하도록 투여 간격을 이전 투여 간격의 50% 이하 범위에서 조절하였다. 결과: 24명의 대상 환자 중 교차 연구를 완결한 환자는 고용량-기존용량군 8명, 기존용량-고용량군 7명이었고, 이들에 대하여 최종분석을 실시하였다. 투여 전, 12주, 24주, 36주, 48주에 혈색소는 고용량-기존용량군에서 10.8±1.1 (이하 평균±표준편차), 11.5±0.9, 11.5±1.5, 11.4±1.5, 11.5±0.8 g/dL이었으며, 기존용량-고용량군에서 11.2±0.8, 11.4±1.2, 11.2±0.9, 11.2±1.4, 11.4±0.9 g/dL로 차이가 없었다. 투여 전, 12주, 24주, 36주, 48주의 epoetin alfa의 평균 투여량은 고용량-기존용량군에서 83.6±38.1, 87.1±35.8, 89.4±34.2, 60.1±25.1, 62.8±30.7 IU/kg/week이었으며 기존용량-고용량군에서 69.8±31.6, 64.9±12.2, 69.9±46.1, 78.8±29.3, 75.9±16.4 IU/kg/week로 고용량 투여시 다소 많은 양상이었으나 유의한 차이는 없었다. 투여간격은 Period I, Period II에서 고용량-기존용량군은 13.3±5.3, 8.2±4.3일, 기존용량-고용량군은 7.0±2.5, 13.4±4.0일이었고, 고용량 투여시와 기존용량 투여시의 투여간격은 13.3±4.8, 7.5±3.4일로 유의한 차이를 보였다. 관찰 기간동안 양 군 모두 혈압의 변화와 요소 청소율(Kt/V)에는 차이가 없었고, 주사 부위 통증은 경미하였다. 결론: 지속성 외래 복막투석 환자에서 epoetin alfa 10,000 IU를 일시에 투여할 경우 4,000 IU 투여에 비하여 거의 비슷한 평균 용량으로 투여 횟수를 감소시킬 수 있었고, 부작용은 경미하였다. Background: Recombinant human erythropoietin (rHuEPO) is an essential and well-established treatment for renal anemia. Rcently, clinicians have moved toward administration of high dose rHuEPO to reduce the inconvenience and time efficient. We aimed to determine whether high dose subcutaneous (SC) epoetin alfa is as efficient and safe as the usual dose for treating anemia in continuous ambulatory peritoneal dialysis (CAPD) patients. Methods: Twenty-four patients on CAPD were randomly assigned to a high-usual dose group (n=12) and an usual-high dose group (n=12) with a variable interval for 48 weeks. Patients received 10 times treatments by scheduled visiting during Period I lasting 24 weeks and received 4 times treatments by scheduled visiting in Period II lasting 24 weeks by cross-over. The high dose was 10,000 IU and the usual dose was 4,000 IU epoetin alfa regimen. If hematocrit was out of the targeted range, 30~39%, the interval of epoetin alfa was changed within 50% of the previous interval. Results: Fifteen patients, out of 24, completed the study (8 patients in the high-usual dose group; 7 patients in the usual-high dose group). Mean hemoglobin levels at randomization and after 12, 24, 36 and 48 weeks were 10.8±1.1, 11.5±0.9, 11.5±1.5, 11.4±1.5, 11.5±0.8 g/dL, respectively, in high-usual dose group compared with 11.2±0.8, 11.4±1.2, 11.2±0.9, 11.2±1.4, 11.4±0.9 g/dL, respectively, in usual-high dose group. The mean weekly epoetin alfa dosages at randomization and after 12, 24, 36 and 48 weeks were 83.6±38.1, 87.1±35.8, 89.4±34.2, 60.1±25.1, 62.8±30.7 IU/kg/week, respectively, in high-usual dose group compared with 69.8±31.6, 64.9±12.2, 69.9±46.1, 78.8±29.3, 75.9±16.4 IU/kg/week, respectively, in usual-high dose group. No statistically significant differences between the two groups were apparent for hemoglobin levels or mean weekly epoetin alfa dosages. Treatment interval at Period I and Period II were 13.3±5.3, 8.2±4.3 days in high-usual dose group compared with 7.0±2.5, 13.4±4.0 days in usual-high dose group with statistically significant differences. Treatment interval in high dose was about two times as longer as usual dose. Adverse events were generally mild and transient, and pain on injection site following subcutaneous administration was rarely reported. Conclusions: This study demonstrates that epoetin alfa 10,000 IU is as efficient and safe as 4,000 IU with a similar weekly dose in CAPD patients. Epoetin alfa 10,000 IU administration can reduce frequency of injections by about one half.(Korean J Med 71:527-534, 2006)

혈역학적으로 안정된 혈액투석환자에서 심장 질환 지표로서 B-type Natriuretic Peptide (BNP), N-terminal pro-BNP Cardiac Troponin T 측정

백현정 ( Hyun Jeong Baek ),김정아 ( Jung Ah Kim ),최소연 ( So Yeon Choi ),도연실 ( Yeon Sil Do ),장은희 ( Eun Hee Jang ),김정인 ( Jung In Kim ),도정호 ( Jung Ho Do ),최성철 ( Sung Chul Choi ),이정은 ( Jung Eun Lee ),허우성 ( Woo S 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.2

목적: 만성 신질환 환자들은 일반인에 비해서 관상 동맥질환과 좌심실 비대가 동반되는 경우가 많다. 일반인에서 Btype Natriuretic Peptide (BNP), N-terminal pro-BNP (NT-proBNP), Cardiac Troponin T (cTnT)가 심질환 진단과 예후 인자로 유용하게 사용되고 있다. 투석 환자에서도 표지자를 이용하여 심질환을 예측할 수 있는지 알아보고자 하였다. 방법: 2004년 9월부터 9개월간 삼성서울병원에서 6개월 이상 투석을 받고 있는 환자 중 급성 심혈관계 질환이 없는 27명을 대상으로 하였다. 같은 날 채혈과 심장초음파 검사를 시행하였다. 결과: BNP, NT-proBNP, cTnT 중앙값 (pg/mL)은 각각 433, 10,598, 0.021이었다. NT-proBNP는 BNP (r= 0.940, p=0.000), cTnT (r=0.504, p=0.009)와 뚜렷한 양의 상관관계를 보였다. BNP, NT-proBNP는 심박출 계수와는 음의 상관관계를 (각각 r=-0.502, p=0.008 vs. r=-0.556, p=0.003), 좌심실 질량 지수와는 양의 상관관계를 보였다 (각각 r=0.619, p=0.001 vs. r=0.718, p=0.000). cTnT는 심박출 계수와 음의 상관관계를 보였으나 (r=-0.513, p=0.007), 좌심실 질량 지수와는 상관관계를 보이지 않았다 (r=0.369, p=0.063). 심박출 계수에 독립적으로 영향을 미치는 인자는 albumin, cholesterol, LDL-cholesterol, NT-proBNP이었고 (R2=0.80), 좌심실 질량 지수에 영향을 미치는 인자는 나이, body mass index, LDL-cholesterol, NT-proBNP, cTnT이었다 (R2=0.78). 결론: 혈액투석을 받고 있는 환자에서도 표지자 측정이 심질환을 예측하는데 도움이 될 것으로 사료된다. Purpose: The prevalence of coronary artery disease and left ventricular hypertrophy (LVH) is higher in patients with chronic kidney disease (CKD) than in the general population. In the general population, BNP, NT-proBNP, and cTnT are useful markers of cardiac disease. Recently, studies on biomarkers in patients with CKD have been reported. However, the effect of renal disease on these markers is still uncertain particularly in hemodialysis patients. We investigated the potential of BNP, NT-proBNP, and cTnT as biomarkers of cardiac disease in hemodialysis patients. Methods: We prospectively studied 27 hemodialysis patients without cardiovascular event within the last 6 months. We performed an echocardiography and blood samples for plasma BNP, NT-proBNP and cTnT. Results: Median BNP, NT-proBNP, and cTnT level (pg/mL) were 433, 10,598, and 0.021, respectively. NT-proBNP was correlated with BNP (r=0.940, p=0.000) and cTnT (r=0.504, p=0.009). There was a negative correlation between BNP and left ventricular ejection fraction (LVEF) (r=-0.502, p=0.008), between NT-proBNP and LVEF (r=-0.556, p=0.003), and between cTnT and LVEF (r=-0.513, p=0.007). There was a positive correlation between BNP and LV mass index (LVMI) (g/m2) (r=0.619, p=0.001). Also, a positive correlation between NT-proBNP and LVMI was shown (r=0.718, p=0.000). There was an insignificant positive correlation between cTnT and LVMI (r=0.369, p=0.063). Albumin, cholesterol, LDL-cholesterol, and NT-proBNP had an independent effect on LVEF (R2=0.80). Age, body mass index, LDL-cholesterol, NT-proBNP, and cTnT had an independent effect on LVMI (R2=0.78). Conclusion: BNP, NT-proBNP, and cTnT may be as a noninvasive diagnostic or prognostic marker of cardiac disease in stable hemodialysis patients.

해저유기퇴적물 수거시스템의 실험 및 수치해석

김도정,박제웅,정우철,김성근,Kim, Do-Jung,Park, Je-Woong,Jeong, Uh-Chul,Kim, Seoung-Gun 해양환경안전학회 2008 海洋環境安全學會誌 Vol.14 No.1

오염된 퇴적물은 연안의 생태계 파괴에 근본적인 원인이 되고 있음에 따라, 선진 외국에서는 1960년대부터 이러한 문제 해결을 위한 새로울 기술개발을 진행하여 오고 있다. 본 연구에서는 유기퇴적물 수거를 위한 시스템 설계 및 개발에 있어서 오탁확산에 의한 2차 오염을 방지하거나 최소화 할 수 있는 Pilot 규모 형태의 흡입식 펌프 준설 시스템을 설계 제작하였으며, 시스템의 성능시험을 통한 적용 가능성을 제시하였다. 시스템 최적화를 위하여 수치해석기법을 통한 퇴적물 수거 시스템의 형상에 대한 성능평가를 수행하고, 제작 시스템의 성능시험에 있어서는 시스템의 정지 상태와 이동 상태에서의 퇴적물 수거 성능에 대한 실험을 수행하였다. 본 연구를 통하여 해저 유기퇴적물의 상부만을 준설할 수 있는 시스템의 개발 가능성을 확인하였다. Contaminated sediments are the actual cause for deterioration of coastal-ecosystem. So the developed countries have been in the process of making an effort to develop new techniques for monitoring and solving this problem since 1960. In this research, suction type pump dredging system of pilot size for collecting the filth from the seabed has been designed and manufactured that can prevent or minimize the secondary pollution by filth diffusion. For the practical use, the application possibility of the developed system has been checked through a system performance test. And, the evaluation of system performance according to the underwater body type has been carried out for system optimization by using CFD. The performance tests for checking the efficiency of sediment collecting system are done under two conditions i.e. when the system is non-operational and when the system is self-propelled. The results of this research showed the possibility of the development of dredging system to remove just the upper parts of filth from seabed.

선미유동 제어용 수직판 제원 변화에 따른 유동특성 연구

김도정,오우준,박제웅,정세민,Kim, Do-Jung,Oh, Woo-Jun,Park, Je-Woong,Jeong, Se-Min 해양환경안전학회 2016 해양환경안전학회지 Vol.22 No.5

이산화탄소 배출량 제한을 의무화하는 EEDI, SEEMP 등의 국제협약에 대응하기 위하여 선박의 에너지 절감장치(ESD, Energy Saving Device) 관련 국내기술 대응이 절실하다. 본 연구는 국내 중소형 조선소의 주력선종 효율 향상의 ESD를 설계하기 위하여 유동특성 분석에 대한 연구이다. 프로펠러 상단으로 유입되는 유동을 개선하기 위하여 bare hull의 선미벌브 및 빌지 주변의 유동특성을 수치해석과 모형시험을 통하여 정성적으로 분석하였으며, 선저압력 지점의 개선 및 프로펠러 상단 유입의 선미 빌지 유동 제어를 위하여 선미벌브와 빌지 사이에 수직평판을 부착하였다. 선미 선체표면 압력회복으로 전저항이 약 3.04 % 감소하였으며, 프로펠러 상단 유동 제어를 통해 평균 공칭반류가 약 18.8 % 감소하였다. To cope with international regulations, such as Energy Efficiency Design Index (EEDI), Ship Energy Efficiency Management Plan (SEEMP) and so forth, and to enforce limitations on $CO_2$ emissions, green-ship technology to lower fuel consumption has been actively researched, and the development of an energy-saving device (ESD) is being pursued. In order to design an ESD for small and medium-sized domestic vessels, an analysis on flow characteristics has been performed in the present study. Through a model test and numerical analyses, the characteristics of flow around the stern bilge and bulb have been compared to improve wake quality and resistance performance. As a result of these comparisons and analyses, a vertical plate has been adopted,, as a new ESD. Design criteria for the proposed ESD are also suggested. By applying this new ESD, it is expected that the total resistance and average nominal wake can be reduced by 3.04 % and 18.8 %, respectively.

45노트급 고속정의 초기선형 개발과 저항성능에 관한 연구

김주남(JU-NAM KIM),정우철(UH-CHEUL JEONG),박제웅(JE-WOONG PARK),김도정(DO-JUNG KIM) 한국해양공학회 2006 韓國海洋工學會誌 Vol.20 No.1

The initial hull form of a 100 ton, 45 knot class high-speed craft is newly developed. The resistance performances are investigated using a model test at high speed in a circulating water channel. The effect of the initial trim is studied together. Wave patterns are observed to clarify the relationship between the resistance performance and the wave characteristics. It can be found that the initial trim plays a role in increasing the resistance performance above a certain velocity.